New Drug Treats Pediatric Achondroplasia.

The Food and Drug Administration has granted accelerated approval to vosoritide (Voxzogo) to treat children ages five years and older with achondroplasia who still have open epiphyses.Children prescribed vosoritide should have a meal and 240 to 300 mL of fluid in the hour prior to drug administration to prevent hypotensive episodes.